Q2 STOCKS TO BUY

JPMorgan Says Drug Stock Can't Live Up to High Expectations

This marks the first equivalent of a "sell" rating on MRTX

Aug 2, 2019 at 10:19 AM
facebook X logo linkedin


Mirati Therapeutics Inc (NASDAQ:MRTX) shares have had a huge year, rallying from the low $40 area to a record high of $111.99 on July 31. However, the cancer drug producer has shed 4.9% today to trade at $99.47, following a bear note out of J.P. Morgan Securities. The brokerage firm downgraded its view on MRTX to "underweight" from "neutral," and dropped its price target by $16 to $85, citing expectations that are too high around the company's MRTX849 drug, which is being tested to treat colorectal and lung cancer patients. The analyst in coverage said the current stock price doesn't reflect the short-term risks around Mirati.

Surely, most other analysts have been bullish on MRTX shares, and today's note from J.P. Morgan Securities actually represents the first equivalent of a "sell" to hit the book. By the numbers, seven of the other 12 covering brokerage firms consider the stock a "strong buy."

Many other traders have already been upping the bearish ante on the oncology specialist. That is, short interest increased over 26% in the last two reporting periods. Almost 24% of the total float is now dedicated to short interest, and it would take these bears more than eight days to cover their positions.

And while the security sees little absolute volume in the options pits, those who have taken positions on Mirati Therapeutics have been notably put-skewed. The equity's current Schaeffer's put/call open interest ratio (SOIR) comes in at 1.43, and ranks in the 98th annual percentile.

 
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

GRAND SLAM COUNTDOWN

 
 

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.

 

 
 

Follow us on X, Follow us on Twitter